Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada.
+ 3 more risks
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Cannara Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LOVE's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LOVE exceeded the Canadian Pharmaceuticals industry which returned -76.4% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned -24.8% over the past year.
Price Volatility Vs. Market
How volatile is Cannara Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDoes Cannara Biotech (CSE:LOVE) Have A Healthy Balance Sheet?
2 months ago | Simply Wall StIf You Had Bought Cannara Biotech (CSE:LOVE) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today
4 months ago | Simply Wall StAre Insiders Selling Cannara Biotech Inc. (CNSX:LOVE) Stock?
Is Cannara Biotech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LOVE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LOVE is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: LOVE is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LOVE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LOVE is overvalued based on its PB Ratio (1.2x) compared to the CA Pharmaceuticals industry average (0.8x).
How is Cannara Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cannara Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Cannara Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Cannara Biotech competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Cannara Biotech performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LOVE is currently unprofitable.
Growing Profit Margin: LOVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if LOVE's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare LOVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LOVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-9.9%).
Return on Equity
High ROE: LOVE has a negative Return on Equity (-28.81%), as it is currently unprofitable.
How is Cannara Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: LOVE's short term assets (CA$18.9M) exceed its short term liabilities (CA$7.5M).
Long Term Liabilities: LOVE's short term assets (CA$18.9M) exceed its long term liabilities (CA$7.1M).
Debt to Equity History and Analysis
Debt Level: LOVE's debt to equity ratio (26.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LOVE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LOVE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LOVE has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -7.1% each year.
What is Cannara Biotech's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LOVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LOVE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LOVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LOVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LOVE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Zohar Krivorot (42yo)
Mr. Zohar Krivorot is Founder, President, Chief Executive Officer and Director at Cannara Biotech Inc. since December 31, 2018 and also serves as its Chairman. A successful entrepreneur, Mr. Krivorot has f ...
CEO Compensation Analysis
Compensation vs Market: Zohar's total compensation ($USD106.14K) is below average for companies of similar size in the Canadian market ($USD159.20K).
Compensation vs Earnings: Insufficient data to compare Zohar's compensation with company performance.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: LOVE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 58.5%.
Cannara Biotech Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cannara Biotech Inc.
- Ticker: LOVE
- Exchange: CNSX
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$53.248m
- Shares outstanding: 709.97m
- Website: https://cannara.ca
Number of Employees
- Cannara Biotech Inc.
- 333 Decarie boulevard
- Suite 200
- H4N 3M9
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LOVE||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Jan 2019|
|LOVF.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jan 2019|
|8CB||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 2019|
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. It also offers hemp based CBD products through e-commerce platform. The company was founded in 2018 and is headquartered in Montreal, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 08:44|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.